Brilinta Approved in the US to Reduce the Risk of a First Heart Attack or Stroke in High-Risk Patients with Coronary Artery Disease

FDA News, New FDA Approvals
June 1, 2020
A+ A-
Email Print

Article Link: Brilinta Approved in the US to Reduce the Risk of a First Heart Attack or Stroke in High-Risk Patients with Coronary Artery Disease

June 1, 2020 — AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD), the most common type of heart disease.
The approval…

Source: FDA New Drug Approvals

Posted by

Newer Post
Older Post